Evidence map›Paper›PMID 40903555›Full record

ArticleJournal of neurology2025

A new screening tool for early recognition of ATTRv polyneuropathy in clinical practice: AmyloScan

Juliane Sachau, Lena Rhode, Maike F Dohrn, Jan Vollert, Stefanie Rehm, Manon Sendel, Katrin Hahn, Timon Hansen, Stefan Gingele, Thomas Skripuletz and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Juliane SachauDivision of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus D, 24105, Kiel, Germany. juliane.sachau@uksh.de.ORCID http://orcid.org/0000-0001-5787-6562
Lena RhodeDivision of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus D, 24105, Kiel, Germany.
Maike F DohrnDepartment of Neurology, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Jan VollertDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Stefanie RehmDivision of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus D, 24105, Kiel, Germany.
Manon SendelDivision of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus D, 24105, Kiel, Germany.
Katrin HahnDepartment of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health (BIH), Berlin, Germany.
Timon HansenOnkologicum HOPA, Hamburg, Germany.
Stefan GingeleDepartment of Neurology, Hannover Medical School, Hanover, Germany.
Thomas SkripuletzDepartment of Neurology, Hannover Medical School, Hanover, Germany.
Klarissa StürnerDepartment for Neurology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Elena Enax-KrumovaDepartment of Neurology, BG University Hospital Bergmannsheil GmbH, Ruhr-University Bochum, Bochum, Germany.
Ralf BaronDivision of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus D, 24105, Kiel, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary transthyretin (ATTRv) amyloidosis is a progressive multisystem disorder, mainly characterized by cardiac dysfunction and polyneuropathy. Due to its rarity and heterogeneous presentation, diagnosis is often delayed, which has a direct impact on the initiation of treatment and, therefore, span and quality of life. To facilitate early disease recognition, we aimed to develop and validate a new screening tool for early identification of ATTRv amyloidosis with polyneuropathy (AmyloScan

Indexed as

Amyloid Neuropathies, FamilialPolyneuropathiesAdultAgedAged, 80 and overEarly DiagnosisFemaleHumansMaleMiddle AgedSensitivity and SpecificitySurveys and QuestionnairesBedside sensory testCIDPHereditary transthyretin amyloidosisRed flagsTTR silencersTTR stabilizers

Identifiers

PMID40903555
PMCPMC12408649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.